In one paragraphArticle in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Xinyuan Wang *Tianjin Key Laboratory for Industrial Biological Systems and Bioprocessing Engineering, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China.ORCID 0009-0009-3731-8999 Xiwen Wang *Tianjin Key Laboratory for Industrial Biological Systems and Bioprocessing Engineering, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China.
Song Xu *Tianjin Key Laboratory for Industrial Biological Systems and Bioprocessing Engineering, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China.ORCID 0000-0002-8095-0940 Jia ZhengThe First Central Clinical School, Tianjin Medical University, Tianjin, China.
Yan PangTianjin Key Laboratory for Industrial Biological Systems and Bioprocessing Engineering, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China.ORCID 0009-0006-1737-5986 Tingting ChengTianjin Key Laboratory for Industrial Biological Systems and Bioprocessing Engineering, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China.
Ruiqin HanTianjin Key Laboratory for Industrial Biological Systems and Bioprocessing Engineering, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China.
Wei ZhaoTianjin Key Laboratory for Industrial Biological Systems and Bioprocessing Engineering, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China.
Zhiyong Huang *Tianjin Key Laboratory for Industrial Biological Systems and Bioprocessing Engineering, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China.ORCID 0000-0001-5374-3973 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Atrial fibrillation (AF) is the most prevalent clinical arrhythmia, associated with numerous complications, elevated morbidity and mortality rates, and limited therapeutic interventions, which have been confirmed to be related to the intestinal microbiota. However, there is currently limited research on the interaction between gut microbiota and AF. Herein, we integrated the largest Chinese gut microbiota cohort (
Indexed as
Atrial FibrillationGastrointestinal MicrobiomeLactobacillusLipopolysaccharidesAnimalsDisease Models, AnimalFemaleHumansMaleProbioticsRatsRats, Sprague-DawleyLipopolysaccharidesatrial fibrillationcardiovasculargut microbiotaLactobacilluslipopolysaccharides
Identifiers
PMID42212825
PMCPMC13343854
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390